Zhitong Finance App News, Xintai Healthcare (02291) announced that Zhang Yuxin has been transferred from an executive director to a non-executive director and will no longer serve as the company's deputy general manager and chief technical officer, effective March 1, 2024.
Due to Zhang Yuxin's transfer, Zhang Yuxin is no longer the authorized representative of the company as stipulated in section 3.05 of the Listing Rules, and Gao Meiying, the company's co-company secretary and alternate authorized representative, has been appointed as the company's authorized representative as stipulated in section 3.05 of the Listing Rules, effective from March 1, 2024.
In addition, Qiu Kejin was appointed as R&D director of the company's valve division, and Hu Jinpeng was appointed as R&D director of the company's occluder division, which will take effect on March 1, 2024.